3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
3
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
191
Magnetic Resonance Spectroscopy
141
Biopsy
102
pembrolizumab
82
Carboplatin
76
Cisplatin
68
Nivolumab
62
Radiotherapy
51
Paclitaxel
51
Gemcitabine
50
Cyclophosphamide
48
Dexamethasone
46
durvalumab
39
Radiation
39
atezolizumab
36
Pemetrexed
36
olaparib
34
Rituximab
34
venetoclax
33
Etoposide
33
Doxorubicin
32
Lenalidomide
31
X-Rays
30
Prednisone
30
Bevacizumab
30
Docetaxel
28
Disulfides
28
Immunoglobulin G
27
Vincristine
26
Ipilimumab
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Histamine Antagonists
×
30 days
×
Clear all
NCT06305754
2026-05-29
MK-2870-009
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
520 enrolled